AbCellera Biologics (ABCL) said Thursday that Bruker (BRKR) will pay it $36 million up front as part of a settlement of patent litigation between the two companies.
AbCellera said that as part of the settlement and patent license agreement, the company will also receive royalties on sales of Bruker's Beacon Optofluidic platform products through the life of their licensed patents.
Bruker did not immediately respond to MT Newswires' request for comment.
Shares of AbCellera were up 5% in recent early Thursday trading, while Bruker's shares were more than 2% higher.
Price: 3.52, Change: +0.17, Percent Change: +4.96
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments